X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
male (9) 9
aged (8) 8
care and treatment (8) 8
hematology, oncology and palliative medicine (8) 8
metastasis (8) 8
middle aged (8) 8
oncology (8) 8
adult (7) 7
cancer (6) 6
docetaxel (6) 6
prostate cancer (6) 6
aged, 80 and over (5) 5
chemotherapy (5) 5
double-blind method (5) 5
product development (5) 5
cancer therapies (4) 4
clinical trials (4) 4
medical colleges (4) 4
survival (4) 4
analysis (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
bone neoplasms - secondary (3) 3
carcinoma, renal cell - drug therapy (3) 3
double-blind (3) 3
female (3) 3
kaplan-meier estimate (3) 3
kidney neoplasms - drug therapy (3) 3
neoplasm metastasis (3) 3
pain (3) 3
patients (3) 3
prednisone (3) 3
prostatic neoplasms, castration-resistant - drug therapy (3) 3
prostatic neoplasms, castration-resistant - pathology (3) 3
taxoids - administration & dosage (3) 3
treatment outcome (3) 3
abiraterone acetate (2) 2
antineoplastic agents - adverse effects (2) 2
article (2) 2
bone metastases (2) 2
bone neoplasms - drug therapy (2) 2
bone neoplasms - radiotherapy (2) 2
carcinoma (2) 2
castration (2) 2
cells (2) 2
clinical medicine (2) 2
clinical trials as topic (2) 2
disease (2) 2
disease-free survival (2) 2
drug dosages (2) 2
emitting ra-223 (2) 2
enzalutamide (2) 2
hematology (2) 2
iii trial (2) 2
increased survival (2) 2
mitoxantrone (2) 2
mitoxantrone plus prednisone (2) 2
mutation (2) 2
niacinamide - adverse effects (2) 2
niacinamide - analogs & derivatives (2) 2
niacinamide - therapeutic use (2) 2
phenylurea compounds - adverse effects (2) 2
phenylurea compounds - therapeutic use (2) 2
plus prednisone (2) 2
prostatic neoplasms - drug therapy (2) 2
prostatic neoplasms - mortality (2) 2
prostatic neoplasms - pathology (2) 2
prostatic neoplasms, castration-resistant - radiotherapy (2) 2
protein kinase inhibitors - therapeutic use (2) 2
radiation therapy (2) 2
radium - therapeutic use (2) 2
studies (2) 2
sunitinib (2) 2
therapy (2) 2
tumors (2) 2
vegf (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
abiraterone (1) 1
abridged index medicus (1) 1
administration, oral (1) 1
adolescent (1) 1
advanced solid tumors (1) 1
aflibercept (1) 1
androgens (1) 1
androgens - chemistry (1) 1
androstadienes - therapeutic use (1) 1
androstenes - pharmacology (1) 1
anemia (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
animals (1) 1
anti-angiogenesis (1) 1
antigens (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 738 - 746
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1287 - 1294
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 286 - 296
Journal Article
Urology, ISSN 0090-4295, 2017, Volume 104, pp. 150 - 159
Journal Article
The Lancet, ISSN 0140-6736, 02/2018, Volume 391, Issue 10122, pp. 748 - 757
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 417 - 425
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 893 - 900
Journal Article